Home›Screener›LTRN›Profile
D
39/100

Lantern Pharma

LTRNOncology
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Lantern Pharma (LTRN) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[3], including 2 Phase 2[1], 2 Phase 1[2].

No Form 4 insider filings for LTRN were recorded at the SEC in the past 30 days[4].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. ClinicalTrials.gov (2026-04-11) ↗
  4. SEC EDGAR · 0001763950 (2026-04-11) ↗
🔬
Clinical Trials
3
NCT05456256Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05933265Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06132503Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
0 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Oncology)
NUVBNuvation Bio
B
LBPHLongboard Pharmaceuticals
B
SNDXSyndax Pharmaceuticals
C
KURAKura Oncology, Inc.
C
INCYIncyte Corporation
C
Data Provenance
cik1 verified
clinical trial3 verified
insider buy1 verified
trial count3 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR